Simeon George

Simeon George (board member) discloses dealings in 5 companies, chiefly ADARx Pharmaceuticals, Inc., CRISPR Therapeutics AG and Nkarta, Inc. Over a trading history stretching from 28 April 2022 to 14 October 2026, the count stands at 17 filings.

On the open market, the record shows 7 purchases worth €51.9M and 1 sale worth €643k. Purchases outweigh sales by €51.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant and 1 option exercise. So far in 2026, the count stands at 3 purchases and 1 sale.

A typical purchase (the median) is worth €8.8M. On 4 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 16 October 2026: an option exercise of €375k, in CRISPR Therapeutics AG. The latest purchase is recent: it was published 19 days ago, on 29 September 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.